![Text that says Results](/sites/default/files/styles/square_card_l/public/media/images/media-71.jpg.webp?itok=UNXuLIDJ)
Acalabrutinib shows promise in Waldenström’s macroglobulinaemia
Phase 2 trial finds that acalabrutinib is active and well tolerated in people with Waldenström’s macroglobulinaemia
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
Phase 2 trial finds that acalabrutinib is active and well tolerated in people with Waldenström’s macroglobulinaemia
Promising results published in the Journal of Clinical Oncology in November.
We want to hear from you! Please share your experiences in this new survey.
Promising early results of the KEYNOTE-51 study published in the Lancet Oncology
A recent study published by Macmillan Cancer Support has found that most people who have chronic cancer are not getting the support they need.
Over 3,000 people have entered the HORIZONS study into the impact of cancer diagnosis and treatment on everyday life, including 719 people with lymphoma.
A new ‘gene signature’ might help predict who will respond well to traditional chemotherapy and who might need alternative treatment.
A protein called sIL-2R might help predict outcomes in people with classical Hodgkin lymphoma.
Women diagnosed with Hodgkin lymphoma during pregnancy can be successfully treated during pregnancy with no harm to the unborn child.
Focus on... T-cell lymphomas